Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 8/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5530648 | 1.00 | MCHR1 (0.50) | MCHR1ADRA2AALDH1A1SMN1; SMN2HTR1A | |
| SCHEMBL5529401 | 0.92 | MCHR1 (0.53) | MCHR1ADRA2AALDH1A1SMN1; SMN2HTR1A | |
| SCHEMBL5529407 | 0.92 | MCHR1 (0.53) | MCHR1ADRA2AALDH1A1SMN1; SMN2HTR1A | |
| SCHEMBL4028402 | 0.91 | MCHR1 (0.47) | MCHR1ADRA2AHTR1AADRA1AHRH1 | |
| SCHEMBL5521844 | 0.91 | MCHR1 (0.47) | MCHR1ADRA2AHTR1AADRA1AHRH1 | |
| SCHEMBL5524920 | 0.91 | MCHR1 (0.50) | MCHR1ADRA2AALDH1A1HTR1AADRA1A | |
| SCHEMBL5524915 | 0.91 | MCHR1 (0.50) | MCHR1ADRA2AALDH1A1HTR1AADRA1A | |
| SCHEMBL4205452 | 0.91 | MCHR1 (0.50) | MCHR1ADRA2AHTR1AADRA1AHRH1 | |
| SCHEMBL5523903 | 0.91 | MCHR1 (0.50) | MCHR1ADRA2AHTR1AADRA1AHRH1 | |
| SCHEMBL4210370 | 0.90 | MCHR1 (0.49) | MCHR1ADRA2AHTR1AADRA1AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | claimed |
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | MCHR1 1/4885ADRA2A 103/4885ALDH1A1 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.